Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00431015 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)
A Phase 1 study, sponsored by Infinity Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT00431015 is a Phase 1 study that has completed, run by Infinity Pharmaceuticals. The registered enrollment target is 88 participants.
The verdict
NCT00431015, a Phase 1 study, has completed, sponsored by Infinity Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, tolerability and maximum tolerated dose of IPI-504 in patients with non-small cell lung cancer (NSCLC). The study will examine how IPI-504 is absorbed, distributed, metabolized and eliminated by the body. The study will also evaluate the anti-tumor activity of IPI-504.
Interventions
- DRUG IPI-504
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2007-01 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00431015
The ClinicalTrials.gov registry entry for NCT00431015 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Infinity Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IPI-504 is the first listed.
NCT00431015 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00431015 about?
NCT00431015 is a clinical study titled "Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)". The purpose of this study is to determine the safety, tolerability and maximum tolerated dose of IPI-504 in patients with non-small cell lung cancer (NSCLC). The study will examine how IPI-504 is absorbed, distributed, metabolized and eliminated by the body. The study will also evaluate the anti-tum...
What is the current status of trial NCT00431015?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2007-01. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00431015?
The interventions under investigation include: IPI-504 (DRUG).
Who is sponsoring clinical trial NCT00431015?
This trial is sponsored by Infinity Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.